New: NCI-funded clinical trial search
Mednet Logo
CommunityRadiation Oncology

Is it acceptable to give weekly cisplatin for patients with locally advanced head and neck SCC undergoing chemoradiation?

Is there data to support every 3 week dosage v. weekly? https://ascopost.com/news/march-2022/postoperative-weekly-vs-every-3-week-cisplatin-in-chemoradiation-for-locally-advanced-head-and-neck-cancer/
Community PollStarted

How do you administer concurrent cisplatin with radiation for H&N cancer?

153 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet Member
Radiation Oncology · USC Keck School of Medicine
Answered on

@Dr. First Last just presented at the ASCO H&N highlights session that weekly cisplatin 40mg/m2 is now considered a standard of care, at least in the post-op high risk setting based on data by Dr. Kiyota et al. showing superior outcomes, likely due to higher cumulative cisplatin dose (>200mg/m2) com...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Michigan Medical School
Answered on

A number of chemotherapeutic agents have been utilized as radiation sensitizers during concomitant therapy. However, the most commonly used regimens include high-dose cisplatin (100 mg/m2 every 21 days for two or three doses), weekly cisplatin (30-40 mg/m2), weekly carboplatin (AUC=2) plus paclitaxe...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · UC San Diego School of Medicine
Answered on

Recently published data suggests that weekly cisplatin 30 mg/m2 is inferior to high dose cisplatin (1). In a randomized phase III trial comparing high dose cisplatin at 100 mg/m2 to weekly cisplatin, weekly cisplatin resulted in a significantly higher risk of locoregional recurrence and a trend towa...

Join for free or sign in to see the full answer